An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
PHASE1
This is a two-part, Phase I/II, open-label, global, multicenter study asses...
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
PHASE2
This Phase II study aims to evaluate efficacy and safety of the combination...
Status
Active Not Recruiting
Location
University of California San Diego - Moores Cancer Center
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
PHASE2
This Phase II study aims to evaluate the efficacy and safety of the combina...